Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?

Authors


  • Potential conflict of interest: The authors received honorariums from OrthoBiotech Clinical Affairs, LLC, Bridgewater, NJ.

No abstract is available for this article.

Ancillary